Varicose VeinsNCT03326219
Endoveneous Histologic Study
A study testing Clarivein in people with Varicose Veins, run by Rijnstate Hospital at 1 site in Netherlands.
Trial summary
A new technique, mechanochemical endovenous ablation (MOCA), using the ClariVein ® system is recently developed. To date, histopathological data after mechanochemical endovenous ablation are not known. The aim of this study is the histopathological analysis of venous injury using mechanochemical endovenous ablation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Varicose Veins
- What is being tested?
- Clarivein
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteNetherlands
- Study dates
- Jan 2017to Dec 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Elective indication for leg amputation
- Peripheral arterial disease
- Age > 18 years
- Written informed consent
Who cannot join
- Patient is incapable of informed consent
- Pregancy and lactation
- Previous surgical or endovenous treatment of the greater saphenous vein in the amputed leg
- Great saphenous vein is used for bypass surgery
- INR > 1.8
- ASA 5
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Histopathological Study of the Vena Saphena Magna After Mechanochemical Endoveneous Ablation
A new technique, mechanochemical endovenous ablation (MOCA), using the ClariVein ® system is recently developed. To date, histopathological data after mechanochemical endovenous ablation are not known.
The aim of this study is the histopathological analysis of venous injury using mechanochemical endovenous ablation.
Read the detailed description
Background:
Varicose veins are a common problem in the Western world. Epidemiological studies show that one quarter of adults have some form of varicose veins. Women are two to three times more affected than men. The prevalence of varicose veins increases steadily with age and is among the top ten of the complaints that people visit their General Practitioner. The main risk factors are prolonged standing or sitting, pregnancy, gender and age. The symptoms of varicose veins are variable and range from cosmetic complaints to venous ulcers.
Stripping of the great saphenous vein(GSV) has been the golden standard for GSV insufficiency for a long time. It is performed under regional or general anesthesia and has a high recurrence rate of 18-40% at 5 years. In addition, the procedure leads to significant postoperative symptoms, especially pain, hematoma and the risk of injury to the saphenous nerve.
In recent years, endovenous techniques have been developed for the treatment of primary GSV insufficiency. Particularly laser endovenous ablation (EVLA) and radiofrequency ablation (VNUS) became accepted technologies and are widely applied in practice. These thermal-based techniques have the advantage that the surgery can be performed with local anesthesia. In addition, endovenous techniques cause less hematoma, pain, and have superior cosmetics and earlier resumption of normal activities/work compared to the conventional surgical stripping.
Endothermal techniques use heat, which has potential risk to damage surrounding tissues. For this reason, patients are treated with tumiscence anesthesia, requiring multiple punctures around the vein. Most patients experience tumiscence anesthesia as unpleasant. Despite the tumiscence anesthesia, patients may still observe postoperative pain, which may last for weeks.
Laser energy is absorbed and converted into intraluminal heat. This process causes steam bubbles, as described by Proebstle. In previous studies, intraluminal and extraluminal temperature measurements were done during endovenous laser ablation. In addition, acute pathological changes after endovenous laser ablation is studied in a recent study. The loss of laser energy was confined to the inner part of the media. No perivascular damage was seen. However, 1% of patients treated with endovenous laser ablation has nerve damage or paresthesias. It suggests that perivascular damage to some extent still exists.
The effects of foam sclerosis appear to be limited to the endothelium and tunica media of the vein wall. Pathological changes occur rapidly within the first 2 minutes after treatment. After 30 minutes intimal detachment of the tunica media, and the formation of microthrombi are detected. The addition of a balloon injury of the vessel wall prior to foam sclerosis, results in a higher percentage of endothelial damage. However, in practice, the clinical results of foam sclerosis disappointing. The occlusionrate from 1 to 5 years were 81 and 73% in a recent meta-analysis.
A new technique, mechanochemical endovenous ablation (MOCA), using the ClariVein ® system is recently developed. The first studies show that MOCA a safe and effective treatment for varicose veins. This technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique . Tumiscence anesthesia is redundant and complications that occur in thermal endovenous techniques, such as pain, hematoma formation, induration and paresthesias could be reduced. To date, histopathological data after mechanochemical endovenous ablation are not known.
Objective of the study:
The aim of this study is the histopathological analysis of venous injury using mechanochemical endovenous ablation
Study design:
The Endovenous Histology study is a histopathological study on the effects of mechanochemical endovenous ablation. The studycentre will be:
- Rijnstate Hospital, Arnhem.
5 patients with irreversible tissue damage to the lower extremities based on atherosclerotic peripheral vascular disease will be included in the study Endovenous Histology, after signing informed consent. All patients included, are scheduled for an elective upper or underleg amputation. The preprocedural status will be determined by height, weight, comorbidities, ASA classification, medications, previous vascular surgery and venous duplex of the VSM.
Subsequently 5 patients are treated with MOCA of the VSM to the amputation level prior to the amputation under general or spinal anesthesia.
- Conditions
- Varicose Veins
- Being tested
- Clarivein
- Keywords
- MOCA, VSM, Clarivein, Histological
- Medical subject headings
- Varicose Veins
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ClariveinProcedure or surgery
The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .
| Study group | Role | What they receive |
|---|---|---|
| Aethoxysklerol clarivein during leg amp | Other | Clarivein treatment with Aethoxysklerol in 5 patients during lower or upper leg amputation Receives: Procedure: Clarivein |
What is being measured
The primary outcome is the main question the study is designed to answer.
Occlusion of the with Clarivein treated vein
Occlusion of the with the Clarivein (Aethoxysklerol) treated vein, check wheter or not treatment was succesfull.
Measured: 2 years of inclusion and analyzation
Depth of damage inside and/or outside the venous wall
Depth of damage inside and/or outside the venous wall is to check whether or not the venous wall is damaged due to the Clarivein treatment
Measured: 2 years of inclusion and analyzation
Secondary outcomes (3)
Analysis of intraluminal clot / scar
After excision of the treated vein of the amputated leg it will be analysed on intraluminal clot/scar
Measured: 2 years of inclusion and analyzation
Morphological changes of the saphenous nerve due to damage of treatment
Analyses of the changes of the saphenous nerve in the treated area (amputated lef) due to the Clarivein treatment.
Measured: 2 years of inclusion and analyzation
Perivascular damage resulting from treatment
Analyses of the perivascular damage in the amputated leg as a result of the treatment
Measured: 2 years of inclusion and analyzation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Oct 2017
- Study startJan 2017
- Primary completionDec 2019 (estimated)
- Study completionDec 2020 (estimated)
Why it stopped: Difficulty finding eligible patients
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Varicose VeinsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rijnstate Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michel Reijnen, Rijnstate Hospital
- Investigators
- MMPJ Reijnen, MD, Principal investigator, Rijnstate
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03326219
- Sponsor's protocol ID
- NL38948.091.12
- Status last verified
- Nov 2018
- First submitted
- 13 Oct 2017
- Last updated
- 28 Nov 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Histopathological Study of the Vena Saphena Magna After Mechanochemical Endoveneous Ablation
- ClinicalTrials.gov ID
- NCT03326219
- Acronym / sponsor ID
- NL38948.091.12
- Conditions
- Varicose Veins
- Keywords
- MOCA, VSM, Clarivein, Histological
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Difficulty finding eligible patients
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Rijnstate HospitalUniversity, hospital or other
- Study start
- Jan 2017 (actual)
- Primary completion
- Dec 2019 (estimated)
- Study completion
- Dec 2020 (estimated)
- First posted
- 31 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A new technique, mechanochemical endovenous ablation (MOCA), using the ClariVein ® system is recently developed. To date, histopathological data after mechanochemical endovenous ablation are not known.
The aim of this study is the histopathological analysis of venous injury using mechanochemical endovenous ablation.
Detailed description
Background:
Varicose veins are a common problem in the Western world. Epidemiological studies show that one quarter of adults have some form of varicose veins. Women are two to three times more affected than men. The prevalence of varicose veins increases steadily with age and is among the top ten of the complaints that people visit their General Practitioner. The main risk factors are prolonged standing or sitting, pregnancy, gender and age. The symptoms of varicose veins are variable and range from cosmetic complaints to venous ulcers.
Stripping of the great saphenous vein(GSV) has been the golden standard for GSV insufficiency for a long time. It is performed under regional or general anesthesia and has a high recurrence rate of 18-40% at 5 years. In addition, the procedure leads to significant postoperative symptoms, especially pain, hematoma and the risk of injury to the saphenous nerve.
In recent years, endovenous techniques have been developed for the treatment of primary GSV insufficiency. Particularly laser endovenous ablation (EVLA) and radiofrequency ablation (VNUS) became accepted technologies and are widely applied in practice. These thermal-based techniques have the advantage that the surgery can be performed with local anesthesia. In addition, endovenous techniques cause less hematoma, pain, and have superior cosmetics and earlier resumption of normal activities/work compared to the conventional surgical stripping.
Endothermal techniques use heat, which has potential risk to damage surrounding tissues. For this reason, patients are treated with tumiscence anesthesia, requiring multiple punctures around the vein. Most patients experience tumiscence anesthesia as unpleasant. Despite the tumiscence anesthesia, patients may still observe postoperative pain, which may last for weeks.
Laser energy is absorbed and converted into intraluminal heat. This process causes steam bubbles, as described by Proebstle. In previous studies, intraluminal and extraluminal temperature measurements were done during endovenous laser ablation. In addition, acute pathological changes after endovenous laser ablation is studied in a recent study. The loss of laser energy was confined to the inner part of the media. No perivascular damage was seen. However, 1% of patients treated with endovenous laser ablation has nerve damage or paresthesias. It suggests that perivascular damage to some extent still exists.
The effects of foam sclerosis appear to be limited to the endothelium and tunica media of the vein wall. Pathological changes occur rapidly within the first 2 minutes after treatment. After 30 minutes intimal detachment of the tunica media, and the formation of microthrombi are detected. The addition of a balloon injury of the vessel wall prior to foam sclerosis, results in a higher percentage of endothelial damage. However, in practice, the clinical results of foam sclerosis disappointing. The occlusionrate from 1 to 5 years were 81 and 73% in a recent meta-analysis.
A new technique, mechanochemical endovenous ablation (MOCA), using the ClariVein ® system is recently developed. The first studies show that MOCA a safe and effective treatment for varicose veins. This technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique . Tumiscence anesthesia is redundant and complications that occur in thermal endovenous techniques, such as pain, hematoma formation, induration and paresthesias could be reduced. To date, histopathological data after mechanochemical endovenous ablation are not known.
Objective of the study:
The aim of this study is the histopathological analysis of venous injury using mechanochemical endovenous ablation
Study design:
The Endovenous Histology study is a histopathological study on the effects of mechanochemical endovenous ablation. The studycentre will be:
- Rijnstate Hospital, Arnhem.
5 patients with irreversible tissue damage to the lower extremities based on atherosclerotic peripheral vascular disease will be included in the study Endovenous Histology, after signing informed consent. All patients included, are scheduled for an elective upper or underleg amputation. The preprocedural status will be determined by height, weight, comorbidities, ASA classification, medications, previous vascular surgery and venous duplex of the VSM.
Subsequently 5 patients are treated with MOCA of the VSM to the amputation level prior to the amputation under general or spinal anesthesia.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Aethoxysklerol clarivein during leg amp | Other | Procedure: ClariveinClarivein treatment with Aethoxysklerol in 5 patients during lower or upper leg amputation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Elective indication for leg amputation
- Peripheral arterial disease
- Age > 18 years
- Written informed consent
Key exclusion criteria (6 listed)
- Patient is incapable of informed consent
- Pregancy and lactation
- Previous surgical or endovenous treatment of the greater saphenous vein in the amputed leg
- Great saphenous vein is used for bypass surgery
- INR > 1.8
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ClariveinThe Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique . | Procedure or surgery | Aethoxysklerol clarivein during leg amp |
Primary outcome
Occlusion of the with Clarivein treated vein
Time frame: 2 years of inclusion and analyzation
Occlusion of the with the Clarivein (Aethoxysklerol) treated vein, check wheter or not treatment was succesfull.
Depth of damage inside and/or outside the venous wall
Time frame: 2 years of inclusion and analyzation
Depth of damage inside and/or outside the venous wall is to check whether or not the venous wall is damaged due to the Clarivein treatment
3 secondary outcomes
Analysis of intraluminal clot / scar
Time frame: 2 years of inclusion and analyzation
Morphological changes of the saphenous nerve due to damage of treatment
Time frame: 2 years of inclusion and analyzation
Perivascular damage resulting from treatment
Time frame: 2 years of inclusion and analyzation
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2018.
Related trials for Varicose Veins
Not yet recruiting
Phenotyping Rehabilitation for Improving Frailty, Functional Capacity
Varicose Veins
Active, not recruitingObservational study
Pain During Heat Treatment for Lower Extremity Varicose Veins: Radiofrequency vs. Microwave
Lower Extremity Varicose Veins, Radiofrequency Ablation
RecruitingObservational study
Natural History of Noncirrhotic Portal Hypertension
Cystic Fibrosis, Immunologic Deficiency Syndrome
Recruiting
Vacuum Compression Therapy and Tissue Oxygenation in Chronic Leg Ulcers
Leg Ulcers, Leg Ulcers Venous
Recruiting
Dose-Response Structured Calf Muscle Pump Activation Strategies Versus Unsupervised Home Walks
Venous Ulcer of Leg
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
MMPJ Reijnen, MD principal investigator
Rijnstate
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clarivein in people with Varicose Veins, run by Rijnstate Hospital at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 28 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Occlusion of the with Clarivein treated vein (time frame: 2 years of inclusion and analyzation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2018.